Sees FY24 operating loss on a non-GAAP basis below $475M; and cash, cash equivalents and short-term investments $1.7B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IONS:
- Ionis reports fourth quarter and full year 2023 financial results
- IONS Upcoming Earnings Report: What to Expect?
- Ionis Pharmaceuticals confirms FDA orphan designation for olezarsen
- Ionis Pharmaceuticals initiated with a Peer Perform at Wolfe Research
- Ionis Pharmaceuticals’ olezarsen granted FDA orphan designation
